Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 47 publications
Quantifying diffuse airspace disease on portable chest radiographs in acute respiratory failure using the RALE score.
Journal: Intensive care medicine experimental
Published: April 22, 2026
Vixarelimab in Patients With Prurigo Nodularis: A Randomized Clinical Trial.
Journal: JAMA dermatology
Published: December 17, 2025
Randomized, phase I studies to evaluate the safety, tolerability, and pharmacokinetics of an inhaled, TMEM16A potentiator, GDC-6988, in healthy subjects.
Journal: Therapeutic advances in respiratory disease
Published: November 29, 2025
Context-specific genetic effects inform endotypes and treatment in asthma.
Journal: The Journal of allergy and clinical immunology
Published: August 29, 2025
Mechanistic Physiologically Based Pharmacokinetic Modeling of Dry Powder and Nebulized Formulations of Orally Inhaled TMEM16A Potentiator GDC-6988.
Journal: CPT: pharmacometrics & systems pharmacology
Published: November 14, 2024
Astegolimab or Efmarodocokin Alfa in Patients With Severe COVID-19 Pneumonia: A Randomized, Phase 2 Trial.
Journal: Critical care medicine
Published: December 15, 2022
Serious Infection Rates Among Patients with Select Autoimmune Conditions: A Claims-Based Retrospective Cohort Study from Taiwan and the USA.
Journal: Rheumatology and therapy
Published: October 05, 2022
Effects of inhaled JAK inhibitor GDC-4379 on exhaled nitric oxide and peripheral biomarkers of inflammation.
Journal: Pulmonary pharmacology & therapeutics
Published: December 17, 2021
A Phase 1 study of GDC-0134, a dual leucine zipper kinase inhibitor, in ALS.
Journal: Annals of clinical and translational neurology
Published: December 09, 2021
Phase I and scintigraphy studies to evaluate safety, tolerability, pharmacokinetics, and lung deposition of inhaled GDC-0214 in healthy volunteers.
Journal: Clinical and translational science
Published: September 15, 2021
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of the Monoclonal Antibody MHAA4549A in Patients With Acute Uncomplicated Influenza A Infection.
Journal: Open forum infectious diseases
Published: August 16, 2021
Dose-dependent inactivation of airway tryptase with a novel dissociating anti-tryptase antibody (MTPS9579A) in healthy participants: A randomized trial.
Journal: Clinical and translational science
Published: July 15, 2021
Last Updated: 09/26/2026